We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Neuropathic Post-Zosterian Pain on the Cognition

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00989040
Recruitment Status : Completed
First Posted : October 2, 2009
Last Update Posted : January 30, 2012
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Pain is defined as a sensorial and emotional phenomenon and lead consequences on the cognition. These consequences could be increased with usual treatment. So the aim of this study is to explore these cognitive consequences.

Condition or disease Intervention/treatment Phase
Neuropathic Post-zosterian Pain Cognition Drug: usual treatment: Versatis Phase 1

Detailed Description:
Pilot prospective study with parallel groups

Study Design

Study Type : Observational
Actual Enrollment : 100 participants
Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Impact of Neuropathic Post-zosterian Pain on the Cognition (NPZ and Cognition)
Study Start Date : March 2009
Primary Completion Date : June 2009
Study Completion Date : September 2009
Groups and Cohorts

Intervention Details:
    Drug: usual treatment: Versatis
    • To explore if the cognition is failed in treated patients suffering of neuropathic postzosteria pain.
    • To see if treated patients with patch (Versatis®) have better cognition than treated patients without patch.

Outcome Measures

Primary Outcome Measures :
  1. The principal outcome is to explore if the cognition is failed in treated patients suffering of neuropathic post-zosteria pain. [ Time Frame: at day 1 ]

Secondary Outcome Measures :
  1. Study if treated patients with patch (Versatis®) have better cognition than treated patients without patch. [ Time Frame: at day 1 ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients who suffer of neuropathic post-zosteria pain
Criteria

Inclusion Criteria:

  • Patient suffering of NPZ pain
  • Over 55 years old
  • Healthy volunteers
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00989040


Locations
France
CHU Clermont-Ferrand
Clermont-Ferrand, France, 63003
Sponsors and Collaborators
University Hospital, Clermont-Ferrand
Investigators
Principal Investigator: Claude Dubray, PUPH CIC-CPC Clermont-Ferrand
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier: NCT00989040     History of Changes
Other Study ID Numbers: CHU-0049
First Posted: October 2, 2009    Key Record Dates
Last Update Posted: January 30, 2012
Last Verified: January 2012

Keywords provided by University Hospital, Clermont-Ferrand:
NPZ
Pain